teriparatide (Terrosa®)

Status: Medicine does not meet criteria for AWMSG assessment
Excluded from appraisal by AWMSG as meets exclusion criteria 11. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information.
Medicine details
Medicine name	teriparatide (Terrosa®)
Formulation	20 micrograms/80 microlitres solution for injection
Reference number	4255
Indication	Indicated in adults for the treatment of osteoporosis in post-menopausal women and men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture
Company	Gedeon Richter (UK) Ltd
BNF chapter	Endocrine system
Assessment type	N/A
Status	Medicine does not meet criteria for AWMSG assessment
Date of issue	03/05/2019